RXST News

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

RxSight, which sells premium adjustable intraocular lenses used in cataract surgery, raised $118 million by offering 7.4 million shares at $16, the low end of the range of $16 to $18. RxSight markets its RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, to offers the first and only commercially...read more

RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday. The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, RxSight would command a fully diluted market value of $477 million. RxSight markets...read more

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million.  Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to raise $25 million at a $54 million market cap. This oncology biotech develops RNA therapeutics for the treatment of solid...read more